Market research
1UB.F Cognetivity Neurosciences Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 605K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.37
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- CA19243C1005
- Market cap
- 605K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.37
About
About Cognetivity Neurosciences Ltd
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1UB.F discussion.
5 years, 5 months ago
Cognetivity Neurosciences Ltd is currently in a long term uptrend where the price is trading 76.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cognetivity Neurosciences Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 87.3% to $-96K since the same quarter in the previous year.
Finally, its free cash flow grew by 76.7% to $-31K since the same quarter in the previous year.
Based on the above factors, Cognetivity Neurosciences Ltd gets an overall score of 4/5.